Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.4550
+0.0129 (2.92%)
At close: May 1, 2026, 4:00 PM EDT
0.4695
+0.0145 (3.19%)
Pre-market: May 4, 2026, 5:00 AM EDT
Silo Pharma Revenue
In the year 2025, Silo Pharma had annual revenue of $72.10K. Silo Pharma had revenue of $18.03K in the quarter ending December 31, 2025.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
102.65
Revenue / Employee
$24,034
Employees
3
Market Cap
7.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.10K | - | - |
| Dec 31, 2024 | 72.10K | - | - |
| Dec 31, 2023 | 72.10K | - | - |
| Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
| Dec 31, 2021 | 71.26K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Immuron | 4.99M |
| Xenetic Biosciences | 2.98M |
| BioAtla | 2.00M |
| Can-Fite BioPharma | 405.00K |
| Addex Therapeutics | 198.82K |
SILO News
- 4 days ago - Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD - GlobeNewsWire
- 11 days ago - Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents - GlobeNewsWire
- 26 days ago - Silo Pharma Rallies After Securing Key Patent Allowance - Benzinga
- 27 days ago - Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In Focus - Benzinga
- 27 days ago - Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - GlobeNewsWire
- 2 months ago - Silo Pharma Announces Share Buyback Program - GlobeNewsWire
- 2 months ago - Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio - GlobeNewsWire
- 4 months ago - Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewsWire